{
    "clinical_study": {
        "@rank": "109427", 
        "acronym": "MARINER", 
        "arm_group": [
            {
                "arm_group_label": "Rivaroxaban", 
                "arm_group_type": "Experimental", 
                "description": "Each patient will receive either 10 mg or 7.5 mg rivaroxaban tablet once daily orally (by mouth) for 45 days. The dosing will depend on a creatinine clearance at screening."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Each patient will receive matching placebo tablet once daily orally (by mouth) for 45 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared\n      with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and\n      VTE-related death post-hospital discharge in high-risk, medically ill patients."
        }, 
        "brief_title": "A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Heart Failure", 
            "Respiratory Insufficiency", 
            "Stroke Acute", 
            "Infectious Diseases", 
            "Rheumatic Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Communicable Diseases", 
                "Infection", 
                "Heart Failure", 
                "Respiratory Insufficiency", 
                "Rheumatic Diseases", 
                "Stroke", 
                "Thromboembolism", 
                "Venous Thromboembolism"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized (the study medication is assigned by chance), double-blind (neither\n      physician nor participant knows the identity of the assigned treatment), placebo (an\n      inactive substance that is compared with a drug to test whether the drug has a real\n      effect)-controlled, event-driven, multicenter study in patients who are hospitalized for a\n      specific acute medical illness and have other risk factors for venous thromboembolism (VTE).\n      The study is designed to evaluate rivaroxaban in the prevention of symptomatic VTE events\n      and VTE-related deaths for a period of 45 days post-hospital discharge.\n\n      The study will consist of a screening phase, a 45-day double-blind treatment phase, and a\n      30-day follow-up phase. Study drug will start at randomization (Day 1), and will continue\n      until Day 45 (inclusive). A total of approximately 8,000 patients will be randomly assigned\n      to either rivaroxaban or placebo in a 1:1 ratio. The total duration for a patient who\n      completes the study after randomization is expected to be 75 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Must be hospitalized at least 3 consecutive days and up to 14 days for an acute\n             medical condition such as congestive heart failure, acute respiratory insufficiency\n             or acute exacerbation of chronic obstructive pulmonary disease, acute ischemic\n             stroke, acute infectious diseases or inflammatory diseases, including rheumatic\n             disease\n\n          -  Must meet venous thromboembolism (VTE) risk criteria with a total modified Improve\n             VTE Risk Score >=3\n\n        Key Exclusion Criteria:\n\n          -  Any serious bleeding within 3 months prior to randomization or occurring during index\n             hospitalization\n\n          -  Serious trauma within 4 weeks before randomization\n\n          -  History of hemorrhagic stroke at any time in the past\n\n          -  Severe head trauma within 3 months of randomization\n\n          -  Any medical condition that requires chronic use of any parenteral or oral\n             anticoagulation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "8000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02111564", 
            "org_study_id": "CR103834", 
            "secondary_id": [
                "2014-000305-13", 
                "RIVAROXDVT3002"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Rivaroxaban", 
                "description": "Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening >= 50 mL/min will receive 10 mg rivaroxaban tablet with or without food.", 
                "intervention_name": "Rivaroxaban, 10 mg", 
                "intervention_type": "Drug", 
                "other_name": "Xarelto, BAY59-7939"
            }, 
            {
                "arm_group_label": "Rivaroxaban", 
                "description": "Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from 30 to 49 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.", 
                "intervention_name": "Rivaroxaban, 7.5 mg", 
                "intervention_type": "Drug", 
                "other_name": "Xarelto, BAY59-7939"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Heart Failure", 
            "Respiratory Insufficiency", 
            "Stroke Acute", 
            "Infectious Diseases", 
            "Rheumatic Diseases", 
            "Medically ill Patient", 
            "Rivaroxaban", 
            "Thromboembolism", 
            "Prophylactic Anti-Coagulation"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "number_of_arms": "2", 
        "official_title": "Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk", 
        "other_outcome": {
            "description": "At selected sites, blood samples will be collected for pharmacokinetic analysis.", 
            "measure": "Change in blood plasma concentration of rivaroxaban", 
            "safety_issue": "No", 
            "time_frame": "Day 7, Day 21"
        }, 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "This study is not yet recruiting patients. Please check back for future recruiting sites, or email"
        }, 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Canada: Health Canada", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: Danish Medicines Agency", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Hungary: National Institute of Pharmacy", 
                "Israel: Israeli Health Ministry Pharmaceutical Administration", 
                "Italy: The Italian Medicines Agency", 
                "Netherlands: Medicines Evaluation Board (MEB)", 
                "South Africa: Department of Health", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Sweden: Medical Products Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Symptomatic VTE will include lower extremity deep vein thrombosis (DVT) and non-fatal pulmonary embolism (PE).", 
                "measure": "Time from randomization to the first occurrence of symptomatic venous thromboembolism event (VTE) and VTE-related death", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1 up to Day 45"
            }, 
            {
                "description": "Major bleeding will be defined using validated International Society on Thrombosis and Haemostasis (ISTH) bleeding criteria.", 
                "measure": "Time from randomization to the first occurrence of major bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1 up to Day 45"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02111564"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time from randomization to an occurrence of VTE-related death", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1 up to Day 45"
            }, 
            {
                "description": "Symptomatic VTE will include lower extremity DVT and non-fatal PE.", 
                "measure": "Time from randomization to the first occurrence of a symptomatic VTE", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1 up to Day 45"
            }, 
            {
                "measure": "Time from randomization to the first occurrence of a composite of symptomatic VTE and all-cause mortality (ACM)", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1 up to Day 45"
            }, 
            {
                "measure": "Time from randomization to an occurrence of ACM", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1 up to Day 45"
            }
        ], 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}